West Pharmaceutical Services Expects 2024 Sales Of $3B-$3.025B And Adjusted EPS Of $7.50-$7.75 Versus Consensus Of $3.21B and $8.76, Respectively
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical Services projects its 2024 sales to be between $3B-$3.025B with an adjusted EPS of $7.50-$7.75, falling short of the consensus estimates of $3.21B in sales and an EPS of $8.76.
February 15, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
West Pharmaceutical Services' 2024 sales and EPS projections are below market consensus, indicating potential downward pressure on its stock price in the short term.
When a company's financial projections fall short of market consensus, it often leads to negative investor sentiment and can cause the stock price to drop. West Pharmaceutical Services' lower-than-expected 2024 sales and EPS forecasts could disappoint investors, leading to a decrease in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100